Sector News

Merck reorganizing R&D by adding some jobs, cutting others

July 14, 2016
Life sciences

Merck’s big plans for its R&D efforts on both coasts mean it will close an operation in Pennsylvania, costing some jobs there and in New Jersey while adding jobs elsewhere.

The Kenilworth, NJ-based drugmaker today confirmed a report by the In The Pipeline blog about its plans. In an email, the company said Merck Research Laboratories intends to boost its investment in ”exploratory biology,” specifically in Cambridge, MA, and the San Francisco Bay area.

“Unfortunately, these changes will result in workforce reductions at our Kenilworth and Rahway, N.J. sites and our North Wales, Pa. screening facility as we shift resources and personnel,” the company said.

Merck isn’t providing any specific numbers on what the move will mean for jobs at each operation, but it anticipates that it’ll affect less than 10% of discovery, preclinical and early development personnel, including through both separations and employee moves.

The expansion includes new labs in Cambridge that it expects to open late this year. There will also be an interim facility in South San Francisco opening late this year, with about 100 scientists expected to be recruited there. Merck’s looking for a long-term site in that area.

By Eric Palmer

Source: Fierce Pharma

comments closed

Related News

October 2, 2022

GSK names Julie Brown, a 25-year AstraZeneca veteran, its first woman CFO

Life sciences

Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.

October 2, 2022

Moderna creates new launch preparation role, poaches Novartis exec as manufacturing lead

Life sciences

Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.

October 2, 2022

Torrent Pharma to acquire Curatio for $245.16m

Life sciences

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).